Information  X 
Enter a valid email address

Company Name matching 'ProMIS Neurosciences Inc.'

Date
Time Source
Company
Announcement
22 Jul 2021 12:15 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
08 Jul 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
02 Jul 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
08 Jun 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
03 Jun 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
27 May 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
25 May 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
21 May 2021 1:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
19 May 2021 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
14 May 2021 12:00 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces First Quarter 2021 Results
12 May 2021 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
31 Mar 2021 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Fiscal Year 2020 Results
22 Mar 2021 2:44 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
02 Feb 2021 1:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
12 Jan 2021 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Strategic Priorities for 2021
16 Nov 2020 9:48 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Completes Offering of Special Warrants
11 Nov 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Third Quarter 2020 Results
09 Nov 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
05 Nov 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Closes First Tranche of Private Placement
30 Oct 2020 10:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium
29 Oct 2020 10:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board
23 Oct 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
21 Oct 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
13 Oct 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
22 Sep 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease
10 Sep 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
13 Aug 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Second Quarter 2020 Results
29 Jul 2020 6:17 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
09 Jul 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease
24 Jun 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders
17 Jun 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
28 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus
20 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform
19 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
13 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces First Quarter 2020 Results
12 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test
06 May 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
30 Apr 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
22 Apr 2020 7:43 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
15 Apr 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
09 Apr 2020 11:30 am GNW   ProMIS Neurosciences Inc. Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates
07 Apr 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
24 Mar 2020 10:30 am GNW   ProMIS Neurosciences Inc. PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING
18 Mar 2020 10:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
26 Feb 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
25 Feb 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
11 Feb 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
06 Feb 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
29 Jan 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
15 Jan 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board
09 Jan 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
08 Jan 2020 11:30 am GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
31 Dec 2019 6:54 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Completes Second Closing of Private Placement
10 Dec 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
05 Dec 2019 5:50 pm GNW   ProMIS Neurosciences Inc. Aducanumab is good; next generation Alzheimer’s disease therapies will be better
18 Nov 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Completes First Closing of Private Placement
14 Nov 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Third Quarter 2019 Results
13 Nov 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Undertaking $6.5M Private Placement
07 Nov 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease
23 Oct 2019 12:30 pm GNW   ProMIS Neurosciences Inc. ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t